Prevail Therapeutics clinical trials
Acquired by Eli Lilly and Company, Jan 22, 2021 · source ↗
The registry lists 5 studies whose lead sponsor is Prevail Therapeutics. 1 is recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
- 5studies on the registry
- 1open to participants now
- 1reach primary completion within a year
Before and after it joined Eli Lilly and Company
- First submitted before Prevail Therapeutics became part of Eli Lilly and Company
- 3
- First submitted after Prevail Therapeutics became part of Eli Lilly and Company
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Prevail Therapeutics’ studies test, most studies first; none is open now — 3 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
Coming up
1 of Prevail Therapeutics’ studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- 1FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
The study
Add it to your calendar (.ics) → With an account.
All 5 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 220
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Prevail Therapeutics5 studies
Something wrong with this grouping? Tell us on the Eli Lilly and Company page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Eli Lilly and Company studies →
- A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's DiseaseRecruitingNCT06565195Phase 1
Sponsor listed in the registry: Prevail Therapeutics · First submitted after Prevail Therapeutics became part of Eli Lilly and Company
- Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)Active, not recruitingNCT04411654Phase 1/2
Sponsor listed in the registry: Prevail Therapeutics · First submitted before Prevail Therapeutics became part of Eli Lilly and Company
- Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)Active, not recruitingNCT04127578Phase 1/2
Sponsor listed in the registry: Prevail Therapeutics · First submitted before Prevail Therapeutics became part of Eli Lilly and Company
- A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)Active, not recruitingNCT05487599Phase 1/2
Sponsor listed in the registry: Prevail Therapeutics · First submitted after Prevail Therapeutics became part of Eli Lilly and Company
- Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)Active, not recruitingNCT04408625Phase 1/2
Sponsor listed in the registry: Prevail Therapeutics · First submitted before Prevail Therapeutics became part of Eli Lilly and Company